155 related articles for article (PubMed ID: 12946064)
21. Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
Sax PE
AIDS Clin Care; 2008 Dec; 20(12):98. PubMed ID: 19271333
[No Abstract] [Full Text] [Related]
22. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
23. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
Shuter J; Sarlo JA; Rode RA; Zingman BS
HIV Clin Trials; 2009; 10(3):135-42. PubMed ID: 19632952
[TBL] [Abstract][Full Text] [Related]
24. A lame duck, a dark horse, and a goat.
Huff B
GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
26. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859
[No Abstract] [Full Text] [Related]
27. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
[No Abstract] [Full Text] [Related]
28. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
[TBL] [Abstract][Full Text] [Related]
29. The continuing evolution of HIV therapy.
Boyle BA
AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
[No Abstract] [Full Text] [Related]
30. Knee avascular necrosis in HIV patient.
Declet VR; Salas AS
Bol Asoc Med P R; 2015; 107(2):24-6. PubMed ID: 26434077
[No Abstract] [Full Text] [Related]
31. Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.
Gyalrong-Steur M; Bogner JR; Seybold U
Eur J Med Res; 2011 Feb; 16(2):85-92. PubMed ID: 21463988
[TBL] [Abstract][Full Text] [Related]
32. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
33. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
[No Abstract] [Full Text] [Related]
34. Drug profile: atazanavir (Reyataz, ATV).
Pham PA
Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
[No Abstract] [Full Text] [Related]
35. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
Murphy RL; Sanne I; Cahn P; Phanuphak P; Percival L; Kelleher T; Giordano M
AIDS; 2003 Dec; 17(18):2603-14. PubMed ID: 14685054
[TBL] [Abstract][Full Text] [Related]
36. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B;
HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153
[No Abstract] [Full Text] [Related]
37. Atazanavir: a novel HIV-1 protease inhibitor.
Piliero PJ
Expert Opin Investig Drugs; 2002 Sep; 11(9):1295-301. PubMed ID: 12225250
[TBL] [Abstract][Full Text] [Related]
38. [Utility of atazanavir in special populations].
Antela López A
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():49-54. PubMed ID: 20116618
[TBL] [Abstract][Full Text] [Related]
39. New antiretroviral agents.
Gallant JE
Hopkins HIV Rep; 2001 Mar; 13(2):2, 16. PubMed ID: 12184261
[No Abstract] [Full Text] [Related]
40. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]